Core Viewpoint - Recently, the company reported a decline in revenue and incurred losses for the first three quarters of 2025, indicating challenges in its financial performance [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 581 million, a year-on-year decrease of 4.1% [1] - The net profit attributable to the parent company was a loss of 45.92 million [1] - In the third quarter, the operating revenue was 204 million, reflecting a year-on-year decline of 8.9% [1] - The net profit attributable to the parent company for the third quarter was a loss of 14.54 million [1] Regulatory Approvals - During the reporting period, the company received approval from the National Medical Products Administration for the injection of Mycophenolate Mofetil (specification: 0.5g) and obtained drug registration certificates for Nicorandil tablets (specification: 5mg) and Ketorolac Tromethamine injection (specification: 1ml: 30mg) [1] Shareholding Changes - On September 26, 2025, the company was notified by its controlling shareholder, Guangxi Wuzhou Zhongheng Group Co., Ltd. (hereinafter referred to as "Zhongheng Group"), about a capital increase agreement and share transfer agreement signed by its indirect controlling shareholder, Guangxi Investment Group Co., Ltd. (hereinafter referred to as "Guangxi Investment Group") [1] - Guangxi Investment Group plans to increase capital in Guangxi Investment Group Financial Holdings Co., Ltd. (hereinafter referred to as "Guangxi Financial Holdings") by transferring 859,343,587 shares of Zhongheng Group [1] - After the completion of this transaction, Guangxi Financial Holdings will become the indirect controlling shareholder of the company, while Zhongheng Group will remain the direct controlling shareholder, and the Guangxi State-owned Assets Supervision and Administration Commission will continue to be the actual controller of the company [1]

Core Insights - Laimei Pharmaceutical reported a revenue of 581 million yuan and a net loss of 45.91 million yuan for the first three quarters, with a third-quarter revenue of 204 million yuan and a net loss of 14.54 million yuan, indicating a reduction in losses year-on-year [2] Product Developments - The company achieved significant progress with multiple products, enhancing its product pipeline and market competitiveness [2] - Laimei received approval from the National Medical Products Administration for the injection of Mycophenolate Mofetil (0.5g) and registered two other drugs: Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml: 30mg) [2][3] Market Performance - Mycophenolate Mofetil is an immunosuppressant used to prevent acute organ rejection in kidney and liver transplant patients, with sales in China's hospital market projected to grow from 32.89 million yuan in 2022 to 60.59 million yuan in 2024 [2] - Nicorandil tablets, used for treating angina, are expected to see sales increase from 676 million yuan in 2022 to 873 million yuan in 2024 [3] - Ketorolac Tromethamine injection, indicated for moderate to severe postoperative pain, is projected to have sales of 2.643 billion yuan in 2022, decreasing to 898 million yuan by 2024 [3] Future Strategy - The company plans to focus on its strengths in niche markets, continue introducing new products, accelerate the market launch of newly introduced products, and enhance its innovation efforts to navigate opportunities and challenges in the pharmaceutical industry [3]

Core Viewpoint - The announcement highlights that Guangxi Wuzhou Zhongheng Group Co., Ltd.'s subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received drug registration certificates for two medications, Nicorandil Tablets and Ketorolac Tromethamine Injection, which will enhance the company's product line and market presence [1][3]. Group 1: Drug Registration Details - Chongqing Laimei Pharmaceutical has obtained registration for Nicorandil Tablets (5mg) and Ketorolac Tromethamine Injection (1ml:30mg) from the National Medical Products Administration [1][5]. - Nicorandil Tablets are indicated for the treatment of angina pectoris, originally developed by Daiichi Sankyo Co., Ltd. and launched in Japan in 1983, with sales in China starting in 2006 [1][2]. - Sales projections for Nicorandil Tablets in Chinese hospitals from 2022 to 2024 are estimated at CNY 676 million, CNY 789 million, and CNY 873 million, respectively [1][2]. Group 2: Market and Financial Impact - Ketorolac Tromethamine Injection is used for the short-term treatment of moderate to severe postoperative pain, developed by Roche and approved in China in 2005 [2]. - Sales projections for Ketorolac Tromethamine Injection in Chinese hospitals from 2022 to 2024 are estimated at CNY 2.643 billion, CNY 1.892 billion, and CNY 898 million, respectively [2]. - The total R&D investment for Nicorandil Tablets and Ketorolac Tromethamine Injection by Laimei Pharmaceutical is CNY 5.3879 million and CNY 4.7431 million, respectively [2].

Core Insights - Zhongheng Group announced the approval of two drugs by the National Medical Products Administration, indicating a positive development for the company's product portfolio [2] Drug Approval Details - The approved drugs include Nicardipine Tablets (specification: 5mg) and Ketorolac Tromethamine Injection (specification: 1ml: 30mg) [2]

Core Viewpoint - Zhongheng Group has received approval for two new drugs, which may enhance its market position and revenue potential in the pharmaceutical sector [1] Company Summary - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has obtained drug registration certificates for Nicardipine Tablets and Ketorolac Tromethamine Injection from the National Medical Products Administration [1] - As of the latest report, Zhongheng Group's market capitalization stands at 9.3 billion yuan [1] Industry Summary - For the fiscal year 2024, Zhongheng Group's revenue composition is as follows: 76.26% from pharmaceutical manufacturing, 13.84% from other businesses, and 9.9% from food [1]

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for two drug registrations, indicating a positive development in the company's product portfolio and potential revenue growth [1] Group 1: Drug Approvals - The approved drugs include Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml:30mg) [1] - Nicorandil tablets are indicated for the treatment of angina pectoris, which addresses a significant market need in cardiovascular health [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe acute postoperative pain, expanding the company's offerings in pain management [1]

Core Viewpoint - Zhongheng Group's subsidiary, Laimei Pharmaceutical, has received approval from the National Medical Products Administration for two drugs, which will enhance the company's product line [1] Group 1: Drug Approvals - Laimei Pharmaceutical has obtained drug registration certificates for Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml:30mg) [1] - Nicorandil tablets are indicated for the treatment of angina pectoris, while Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe postoperative pain [1] Group 2: R&D Investment - The total R&D investment for Nicorandil tablets was approximately RMB 5.39 million, and for Ketorolac Tromethamine injection, it was around RMB 4.74 million [1] - The approval of these drugs is expected to further enrich the company's product offerings [1]

Core Insights - Zhongheng Group (600252.SH) announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two drugs: Nicardipine Tablets (5mg) and Ketorolac Tromethamine Injection (1ml:30mg) [1] Group 1 - The approval of Nicardipine Tablets and Ketorolac Tromethamine Injection is expected to enhance the company's product line [1]

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received drug registration certificates for two products, which will enhance the company's product line [1] Group 1 - The approved drugs are Nicardipine Tablets (5mg) and Ketorolac Tromethamine Injection (1ml:30mg) [1] - The approval from the National Medical Products Administration is a significant milestone for the company [1] - The addition of these products is expected to contribute positively to the company's growth and market presence [1]

Company Overview - Recently, Laimei Pharmaceutical (SZ 300006, closing price: 4.58 yuan) announced the approval of two drug registration certificates by the National Medical Products Administration for Nicorandil tablets and Ketorolac Tromethamine injection [1] Financial Performance - For the year 2024, Laimei Pharmaceutical's revenue composition is as follows: 84.09% from pharmaceutical manufacturing, 13.06% from pharmaceutical distribution, 1.64% from other businesses, and 1.21% from service income [1] Market Position - As of the report, Laimei Pharmaceutical has a market capitalization of 4.8 billion yuan [1]